Work

RSVpreF Vaccine Elicits a Robust and Durable Immune Response Among Adults Aged 60 Years and Older Across an Entire RSV Season

Year: 2024

Type: conference-abstract

DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2998

Authors: D. Eiras, Y. Fukushima, J. Cardona, J. Qin, J. Woodside, T. Mikati, M. Patton, F. Sakai, E. Kalinina, D. Cooper, K. Koury, A. Anderson, I. Munjal, K. Swanson, A. Gurtman, B. Schmoele-Thoma

Institutions: Pfizer (United States), Pfizer (United Kingdom), Pfizer (Japan), Pfizer (Germany)

Language: English

Topic: Respiratory viral infections research

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4396501919

Cites:

Cited by: 1

Related to: 10